GAVIN OUTTERIDGE How biopharma innovators can benefit from the ACCESS Consortium and CAN/UK/AUS collaboration in HTA GAVIN OUTTERIDGE & BOB CLAY What’s happening now, across
GAVIN OUTTERIDGE The European Union’s new Health Technology Assessment (HTA) Regulation demands that innovative biotech and pharma companies submit a new type of value dossier
GAVIN OUTTERIDGE Building a common value & access strategy for a continent GAVIN OUTTERIDGE, CATHERINE CHAMOUX and RUSLAN HORBLYUK “Who do I call when I
JAYMIN PATEL, RICHARD H. STANFORD & TYLER REINSCH VISIONTherapeutic Numbers It’s the middle of August 2020 and everyone is on the edge of their seat
GAVIN OUTTERIDGE and TYLER REINSCH Recent events have created challenges that no manager or department head could have prepared for. While some companies or departments
ANDY BROGAN and SUSAN HOGUE Balancing access for innovative and transformative medicines with rising healthcare costs is a paramount challenge for the US healthcare system.